



2ND QUARTER 2026

INTERIM REPORT



2ND QUARTER IN BRIEF

- EBITDA¹ NOK 515 million (NOK 522 million)²
- BioSolutions: Higher sales volume with a less favourable product mix
- BioMaterials: High deliveries and record production
- Solid result for Fine Chemicals
- Higher energy, logistics and chemical costs partly offset by lower wood costs
- Impairment of Alginor investment
- Robust cash flow

CONTENTS


The Group	3
Business Areas	5
Foreign Exchange And Hedging	9
Cash Flow And Financial Situation	9
Sustainability	10
Share Information	11
Other Matters And Subsequent Events	11
Outlook	12
The Group's Interim Condensed Financial Statements ...	14
Alternative Performance Measures	25




THE GROUP

Amounts in NOK million	Note	1.4-30.6		1.1-30.6		1.1-31.12
		2026	2025	2026	2025	2025
Operating revenues	2	2,114	2,045	4,119	4,081	7,713
EBITDA ¹		515	522	943	1,033	1,878
Operating profit		337	378	613	745	1,287
Profit/loss before taxes	2	-45	326	185	645	864
Earnings per share (NOK)		-1.27	2.56	0.55	5.08	6.22
Net interest-bearing debt ¹	11	2,141	2,355	2,141	2,355	2,090
Equity ratio ¹ (%)		59.0	57.0	59.0	57.0	60.8
Leverage ratio ¹		1.20	1.20	1.20	1.20	1.11
Return on capital employed ¹ (%)		14.4	17.2	14.4	17.2	15.7


OPERATING REVENUES




EBITDA¹



EBITDA MARGIN¹



EARNINGS PER SHARE CUMULATIVE



¹ [Alternative Performance Measures](#), see page 25 for definition.

SECOND QUARTER

Operating revenues increased to NOK 2,114 million (NOK 2,045 million) in the 2nd quarter of 2026. EBITDA¹ was NOK 515 million (NOK 522 million). The results in BioMaterials and Fine Chemicals increased, while BioSolutions had a lower result compared with the 2nd quarter of 2025.

In BioSolutions, higher sales volume was more than offset by higher energy and energy-related costs, negative currency effects, and a less favourable product mix. For BioMaterials, high deliveries of speciality cellulose were partly offset by lower sales prices and a weaker product mix. A record production contributed positively to the result. In Fine Chemicals, higher deliveries and a favourable product mix were the main reasons for the improved result. Net currency effects were slightly positive for the Group.

Wood costs in the 2nd quarter were approximately 15% lower compared with the 2nd quarter last year. The Middle East conflict had a negative impact on Borregaard's energy, logistics and chemical costs in the 2nd quarter. The net cost impact on raw materials, energy and logistics was approximately NOK 40 million compared with the 2nd quarter 2025.

Other income and expenses¹ were NOK -30 million in the 2nd quarter of 2026 related to ground stabilisation measures at the Sarpsborg site. See Note 3.

Operating profit was NOK 337 million (NOK 378 million). Net financial items were NOK -382 million (NOK -52 million) which include an impairment loss related to Borregaard's investment in Alginor of NOK -337 million. See Other matters and subsequent events and Note 4 and 14.

Profit before tax was NOK -45 million (NOK 326 million). The tax expense of NOK -78 million (NOK -75 million). The tax rate was impacted by the ground stabilisation measures and impairment of the investment in Alginor (see Note 5 and 14).

Earnings per share were NOK -1.27 (NOK 2.56). Excluding the ground stabilisation measureas and impairment of Alginor, earnings per share were NOK 2.35.

The cash flow from operating activities was NOK 695 million (NOK 385 million). The strong cash flow was due to a significant reduction in net working capital and the cash effect from a solid EBITDA¹. The impairment loss related to Alginor had no cash flow effect.

FIRST HALF

Borregaard's operating revenues increased to NOK 4,119 million (NOK 4,081 million) in the 1st half of 2026. EBITDA¹ was NOK 943 million (NOK 1,033 million). Compared with the 1st half of 2025, the results increased in Fine Chemicals, were stable in BioMaterials, and declined in BioSolutions.

Higher energy and energy-related costs, a less favourable product mix, and negative net currency effects were the main reasons for the lower result in BioSolutions. In BioMaterials, higher deliveries of speciality cellulose were offset by lower sales prices and a weaker product mix. High production output contributed positively to the result. Higher deliveries and a favourable product mix were the main reason for the improved result in Fine Chemicals. The net currency effects were slightly positive for the Group.


Other income and expenses¹ were NOK -30 million in the 1st half of 2026 and relates to ground stabilisation measures at the Sarpsborg site. See Note 3.

Operating profit was NOK 613 million (NOK 745 million). Net financial items amounted to NOK -428 million (NOK -100 million) which include an impairment loss related to Borregaard's investment in Alginor of NOK -337 million. See Other matters and subsequent events and Note 4 and 14. Profit before tax was NOK 185 million (NOK 645 million). The tax rate was impacted by an impairment of the investment in Alginor (see Note 5 and 14).

Earnings per share were NOK 0.55 (NOK 5.08). Excluding the ground stabilisation measures and impairment of Alginor, the tax rate was 24% and earnings per share were NOK 4.17. See Note 5, 6 and 14.

In the 1st half of 2026, cash flow from operating activities was NOK 772 million (NOK 514 million). The cash flow improvement was mainly due to a more favourable development in net working capital. The impairment loss related to Alginor had no cash flow effect.

CASH FLOW FROM OPERATING ACTIVITIES



¹ Alternative Performance Measures, see page 25 for definition.
² Figures in parentheses are for the corresponding period in the previous year.

BUSINESS AREAS

BIOSOLUTIONS

	1.4-30.6		1.1-30.6		1.1-31.12
Amounts in NOK million	2026	2025	2026	2025	2025
Operating revenues	1,153	1,149	2,220	2,328	4,396
EBITDA ¹	306	338	566	687	1,209
EBITDA margin ¹ (%)	26.5	29.4	25.5	29.5	27.5


SECOND QUARTER

Operating revenues in BioSolutions were NOK 1,153 million (NOK 1,149 million). EBITDA¹ was NOK 306 million (NOK 338 million).


Higher sales volume was more than offset by higher energy and energy-related costs, negative net currency effects, and a less favourable product mix compared with the same quarter last year.

The average price in sales currency was marginally higher compared with the same quarter in 2025, while total sales volume was 4% higher.

AVERAGE GROSS SALES PRICE³



SALES VOLUME



¹ [Alternative Performance Measures](#), see page 25 for definition.
³ Average sales price is calculated using actual FX rates, excluding hedging impact.
⁴ Metric tonne dry solid.

FIRST HALF

In the 1st half of 2026, BioSolutions' operating revenues were NOK 2,220 million (NOK 2,328 million). EBITDA¹ reached NOK 566 million (NOK 687 million).

Higher energy and energy-related costs, a less favourable product mix, and negative net currency effects were the main reasons for the lower result compared with the same period last year.

Both average price in sales currency and total sales volume were marginally higher than in the 1st half of 2025.



¹ [Alternative Performance Measures](#), see page 25 for definition.

² Figures in parentheses are for the corresponding period in the previous year.

BIOMATERIALS

Amounts in NOK million	1.4-30.6		1.1-30.6		1.1-31.12
	2026	2025	2026	2025	2025
Operating revenues	773	741	1,502	1,430	2,691
EBITDA ¹	151	143	253	256	495
EBITDA margin ¹ (%)	19.5	19.3	16.8	17.9	18.4

SECOND QUARTER

Operating revenues in BioMaterials increased to NOK 773 million (NOK 741 million). EBITDA¹ reached NOK 151 million (NOK 143 million).

High deliveries of speciality cellulose were partly offset by lower sales prices and a weaker product mix. A record production in the quarter contributed positively to the result. Lower wood costs were more than offset by cost increases, mainly related to energy and certain chemicals. Net currency effects were positive.

The average price in sales currency was 4% lower compared with the 2nd quarter of 2025.


FIRST HALF

Operating revenues reached NOK 1,502 million (NOK 1,430 million). EBITDA¹ was NOK 253 million (NOK 256 million).


Higher deliveries of speciality cellulose were partly offset by lower sales prices and a weaker product mix. High production output contributed positively to the result. Cost increases, mainly related to energy and certain chemicals, were partly offset by lower wood costs. Net currency effects were positive.

The average price in sales currency was 4% lower than in the same period last year.

AVERAGE GROSS SALES PRICE⁵



SALES VOLUME



¹ [Alternative Performance Measures](#), see page 25 for definition.
² Figures in parentheses are for the corresponding period in the previous year.
⁵ Average sales price is calculated using actual FX rates, excluding hedging impact.
⁶ Metric tonne

FINE CHEMICALS

Amounts in NOK million	1.4-30.6		1.1-30.6		1.1-31.12
	2026	2025	2026	2025	2025
Operating revenues	198	168	418	347	670
EBITDA ¹	58	41	124	90	174
EBITDA margin ¹ (%)	29.3	24.4	29.7	25.9	26.0

SECOND QUARTER

Fine Chemicals’ operating revenues reached NOK 198 million (NOK 168 million). EBITDA¹ increased to NOK 58 million (NOK 41 million).


Higher deliveries and a favourable product mix within fine chemical intermediates, as well as high deliveries of bioethanol, were the main reasons for the improved result in Fine Chemicals. The net currency impact was positive.

FIRST HALF

Operating revenues in Fine Chemicals increased to NOK 418 million (NOK 347 million). EBITDA¹ reached NOK 124 million (NOK 90 million).

Higher deliveries and a favourable product mix within fine chemical intermediates and high deliveries of bioethanol, were the main reasons for the improved result in Fine Chemicals. The net currency impact was positive.

FINE CHEMICALS - OPERATING REVENUES



¹ [Alternative Performance Measures](#), see page 25 for definition.

FOREIGN EXCHANGE AND HEDGING

Borregaard has a significant currency exposure, which is managed according to the company’s hedging strategy. This strategy delays the impact of currency rate fluctuations. In comparison with the 2nd quarter of 2025, the net impact of foreign exchange on EBITDA¹, including hedging effects, was NOK 5 million. Hedging effects were NOK 74 million (NOK -34 million) in the quarter.	In the 1st half of 2026, the net impact of foreign exchange on EBITDA¹, including hedging effects, was NOK 5 million. Hedging effects were NOK 90 million (NOK -129 million). Assuming currency rates as of 15 July 2026 (USD 9.73 and EUR 11.10) and based on currency exposure forecasts, Borregaard expects a net impact of foreign exchange on EBITDA¹ of	approximately NOK 10 million in the 3rd quarter of 2026 and NOK 45 million for the full year of 2026, compared with the corresponding periods in 2025.
--	--	--

CASH FLOW AND FINANCIAL SITUATION

SECOND QUARTER

Cash flow from operating activities was NOK 695 million (NOK 385 million). The strong cash flow was due to a significant decrease in net working capital and the cash effect from a solid EBITDA¹. The impairment loss related to Alginor had no cash flow effect.	Investments amounted to NOK 355 million (NOK 382 million). Replacement investments were NOK 149 million (NOK 212 million) and expansion investments¹ totalled NOK 206 million (NOK 170 million). The largest expenditures were related to the upgrade of the electricity transformation capacity and the deblocking project at the Sarpsborg site, in addition to capital raises (convertible loans) in Alginor.	On 30 June 2026, the Group has net interest-bearing debt¹ totalling NOK 2,141 million (NOK 2,355), an increase of NOK 51 million from year-end 2025.
--	--	--

HALF YEAR (1.1-30.6)

In the 1st half of 2026, cash flow from operating activities was strong, reaching NOK 772 million (NOK 514 million). The cash flow improvement was mainly due to a more favourable development in net working capital. The impairment related to Alginor had no cash flow effect.	Dividend of NOK 475 million (NOK 424 million) was paid out in the 2nd quarter. In the 1st half of 2026, the Group has sold and repurchased treasury shares with net proceeds of NOK -18 million (NOK 20 million). Realised effect of hedging of net investments in subsidiaries was NOK 27 million (NOK 100 million).	At the end of June, the Group was well capitalised with an equity ratio¹ of 59.0% (57.0%) and a leverage ratio¹ of 1.20 (1.20).
---	--	--

¹ [Alternative Performance Measures](#), see page 25 for definition.

SUSTAINABILITY

Environment, health and safety (EHS) are integral parts of Borregaard’s business model.

Greenhouse gas emissions (Scope 1 and 2) increased by 6% the last twelve months compared with the level at the end of 2025. This was mainly due to increased production and reduced use of renewable energy at the Sarpsborg site. The rolling twelve-months average for COD emissions remained at the same level as at the end of 2025.

There were no fatal or high-consequence work-related injuries in the first half of 2026. The total recordable injuries per million hours worked (TRIF) were reduced to 5.5 (6.8 at year-end 2025). There were no lost-time injuries during the last twelve months. Sick leave over the last twelve months was reduced to 3.5%.

The table below shows key sustainability measures and targets.

All figures are rolling 12 months	30.06.2026	31.12.2025	Target 2026	Long-term target 2030
Greenhouse gas emissions (Scope 1 and 2, `000 tonnes)*	177	167	< 163	< 114 **
COD (organic material) in process water discharged	47 t/day	47 t/day	<46 t/day	< 40 t/day
Total recordable injuries per million hours worked	5.5	6.8	< 3,5	0
Sick leave % ***	3.5 %	3.4 %	< 3.4%	< 3.0%

*Emission figure are based on the best estimate at the time of reporting
**42% reduction from base year 2020
*** Based on updated calculation method from The Federation of Norwegian Industries



¹ [Alternative Performance Measures](#), see page 25 for definition.

SHARE INFORMATION

During the 2nd quarter of 2026, Borregaard has repurchased a total of 300,000 treasury shares at an average price of NOK 145.98. For more information, see notifications to the Oslo Stock Exchange on 8, 20 and 27 May 2026.

Total number of shares outstanding on 30 June 2026 was 100 million, including 355,404 treasury shares. Total number of shareholders was 11,392. Borregaard ASA’s share price was NOK

149.00 at the end of the 2nd quarter (NOK 199.40 at the end of 2025).

OTHER MATTERS AND SUBSEQUENT EVENTS

PROPOSED RESTRUCTURING AND IMPAIRMENT OF ALGINOR

In recent months, Alginor has faced challenges relating to raw material supply, delays in product development and commercialisation, and further cost overruns associated with the investment in its demonstration plant. See notification to the Oslo Stock Exchange on 28 May 2026.

Borregaard considers it unlikely that the current value of Alginor exceeds the company's bank debt and other prioritised obligations. Accordingly, Borregaard's view is that its shareholding in Alginor and convertible loans to the company have no recoverable value.

Against this background and based on a proposed share transactions at no consideration between Borregaard and Hatteland, Borregaard has recognised an impairment loss of NOK 337 million in the 2nd quarter relating to its equity investment in Alginor and the convertible loans granted to the company. Following the impairment, the carrying value of Borregaard’s investment in Alginor is reduced to nil as of 30 June 2026.

The three main shareholders in Alginor – Borregaard, Must Invest and Hatteland – have offered to guarantee for NOK 100 million in new equity for Alginor, with Hatteland acting as lead investor. The offer is subject to corporate approvals in Alginor.

Borregaard has committed to subscribe for up to NOK 10 million of the proposed NOK 100 million equity injection. Upon completion of the proposed restructuring, Borregaard’s ownership interest in Alginor will be 10%. For more information, see <https://alginor.no/investors/reports-information/>.

ANTI-DUMPING

In August 2025, RYAM and the United Steelworkers Union filed petitions with US authorities seeking anti-dumping duties on speciality cellulose from Borregaard.

Borregaard disputes the basis for the allegations, both regarding the data presented and the underlying arguments. Borregaard has engaged legal and accounting experts to manage its defense.

In the 2nd quarter of 2026, Borregaard was assigned a preliminary anti-dumping duty margin of 6.54%, with a final decision anticipated in October 2026.

GROUND STABILISATION MEASURES

In connection with Østfold County's planned construction of a new bridge across the Glomma River, the County Authority has identified a requirement for stabilisation measures at the Borregaard's site to mitigate the risk of landslides. The measures are intended to minimise the risk of additional requirements which could affect Borregaard’s day-to-day operations.

As of 30 June 2026, Borregaard has accrued NOK 30 million related to the planned stabilisation measures. The cost is recognised as part of Other income and expenses¹. See Note 3.

¹ [Alternative Performance Measures](#), see page 25 for definition.

OUTLOOK

For BioSolutions, sales volume for 2026 is forecast to be 335,000 tonnes. Sales volume in the 3rd quarter is expected to be approximately 85,000 tonnes.

For BioMaterials, sales volume is forecast to exceed 160,000 tonnes in 2026. Sales volume of highly specialised grades is expected to be higher than in 2025. In the 3rd quarter, sales volume is expected to be approximately 40,000 tonnes.

Sales prices for bioethanol are expected to be largely in line with 2025. Sales volume for fine chemical intermediates is expected to increase compared with 2025. Deliveries of bioethanol are expected to be lower, and the product mix for fine chemical intermediates will be weaker in the 2nd half of 2026 compared with the 1st half of the year.

Borregaard's wood costs in the 2nd half of 2026 are expected to be 3-4% lower compared with the 1st half of 2026.

Uncertainty in the global economy related to wars, conflicts, and tariffs is expected to continue impacting the cost of energy and key chemicals, as well as markets and currencies.

Borregaard is implementing a cost improvement programme targeting annual cost savings of NOK 150 million. The savings are expected to be realised gradually, with the full annual effect from 2028.

Sarpsborg, 15 July 2026.
The Board of Directors of Borregaard ASA



STATEMENT BY THE BOARD OF DIRECTORS

We confirm that, to the best of our knowledge, the unaudited interim condensed financial statements for the period 1 January to 30 June 2026, have been prepared in accordance with IAS 34 Interim Financial Reporting, and that the information in the financial statements gives a true and fair view of the business

of the Group and the Group’s assets, liabilities, financial position and overall results, and that the half year report provides a fair overview of the information set out in the Norwegian Securities Trading Act section 5-6, fourth paragraph.

Sarpsborg, 15 July 2026
The Board of Directors of Borregaard ASA

Signed
HELGE AASEN
Chair

Signed
MARGRETHE HAUGE

Signed
ARUNDEL KRISTIANSEN

Signed
TERJE ANDERSEN

Signed
MAGNUS KROGH ANKARSTRAND

Signed
TOM ERIK FOSS-JACOBSEN
CEO

Signed
TOVE ANDERSEN

Signed
RAGNHILD ANKER EIDE



CONTENTS

THE GROUP'S INTERIM CONDENSED FINANCIAL STATEMENTS

The Group's Interim Condensed Income Statement	15
Interim Earnings Per Share.....	15
The Group's Interim Condensed Comprehensive Income Statement.....	15
The Group's Interim Condensed Statement Of Financial Position.....	16
Interim Condensed Changes In Equity	16
The Group's Interim Condensed Cash Flow Statement.....	17
Notes	18
Alternative Performance Measures	25



THE GROUP'S INTERIM CONDENSED INCOME STATEMENT

Amounts in NOK million	Note	1.4-30.6		1.1-30.6		1.1-31.12
		2026	2025	2026	2025	2025
Operating revenues	2	2,114	2,045	4,119	4,081	7,713
Operating expenses		-1,599	-1,523	-3,176	-3,048	-5,835
Depreciation property, plant and equipment		-148	-142	-300	-285	-587
Amortisation intangible assets		-	-2	-	-3	-4
Other income and expenses ¹	3	-30	-	-30	-	-
Operating profit		337	378	613	745	1,287
Financial items, net	4, 14	-382	-52	-428	-100	-423
Profit before taxes		-45	326	185	645	864
Income tax expense	5	-78	-75	-134	-150	-264
Profit for the period		-123	251	51	495	600
Profit attributable to non-controlling		4	-4	-4	-11	-20
Profit attributable to owners of the parent		-127	255	55	506	620
EBITDA ¹		515	522	943	1,033	1,878

INTERIM EARNINGS PER SHARE

Amounts in NOK		1.4-30.6		1.1-30.6		1.1-31.12
		2026	2025	2026	2025	2025
Earnings per share (100 mill. shares)	6	-1.27	2.56	0.55	5.08	6.22
Diluted earnings per share	6	-1.27	2.56	0.55	5.08	6.22

¹ [Alternative Performance Measures](#), see page 25 for definition.

THE GROUP'S INTERIM CONDENSED COMPREHENSIVE INCOME STATEMENT

Amounts in NOK million	Note	1.4-30.6		1.1-30.6		1.1-31.12
		2026	2025	2026	2025	2025
Profit for the period		-123	251	51	495	600
Items not to be reclassified to P&L						
Actuarial gains and losses (after tax)		-	-	-	-	31
Total		-	-	-	-	31
Items to be reclassified to P&L						
Change in hedging-reserve after tax (cashflow)	8	-90	81	162	510	569
Change in hedging-reserve after tax (net investment in subsidiaries)	8	-14	23	14	78	80
Translation effects		26	-25	-20	-103	-110
Total		-78	79	156	485	539
The Group's comprehensive income		-201	330	207	980	1,170
Comprehensive income non-controlling interests		4	-5	-4	-15	-24
Comprehensive income to owners of the parent		-205	335	211	995	1,194

THE GROUP'S INTERIM CONDENSED STATEMENT OF FINANCIAL POSITION

Amounts in NOK million	Note	30.6.2026	31.12.2025
Intangible assets	13	73	79
Property, plant and equipment	13	5,243	5,255
Right-of-use assets		408	445
Other assets	9	559	493
Investments in associate companies	4, 14	18	270
Non-current assets		6,301	6,542
Inventories		1,396	1,521
Receivables	9	1,684	1,516
Cash and cash deposits	11	125	91
Current assets		3,205	3,128
Total assets		9,506	9,670
Group equity	10	5,589	5,853
Non-controlling interests		21	25
Equity		5,610	5,878
Provisions and other liabilities		417	393
Interest-bearing liabilities	9, 11	1,646	1,718
Non-current liabilities		2,063	2,111
Interest-bearing liabilities	9, 11	620	463
Other current liabilities	9	1,213	1,218
Current liabilities		1,833	1,681
Equity and liabilities		9,506	9,670
Equity ratio ¹		59.0%	60.8%

INTERIM CONDENSED CHANGES IN EQUITY

Amounts in NOK million	Note	1.1-30.6.26		1.1.-31.12.25		Total equity
		Controlling interests	Non-controlling interests	Controlling interests	Non-controlling interests	
Equity 1 January		5,853	25	5,878	5,041	5,090
Profit/loss for the period		55	-4	51	620	600
Items in Comprehensive Income	8	156	-	156	574	570
The Group's Comprehensive income	8	211	-4	207	1,194	1,170
Paid dividend		-475	-	-475	-424	-424
Buy-back of treasury shares		-68	-	-68	-30	-30
Exercise of share options		22	-	22	22	22
Shares to employees		37	-	37	34	34
Option costs (share based payment)		9	-	9	16	16
Transactions with non-controlling interests		-	-	-	-	-
Equity at the end of the period		5,589	21	5,610	5,853	5,878

¹ [Alternative Performance Measures](#), see page 25 for definition.

THE GROUP'S INTERIM CONDENSED CASH FLOW STATEMENT

Amounts in NOK million	Note	1.4-30.6		1.1-30.6		1.1-31.12.
		2026	2025	2026	2025	2025
Profit before taxes		-45	326	185	645	864
Amortisation, depreciation and impairment charges		148	144	300	288	591
Changes in net working capital, etc.		325	33	114	-228	-124
Dividend/share of profit from associate companies	4, 14	348	9	364	26	290
Taxes paid		-81	-127	-191	-217	-265
Cash flow from operating activities		695	385	772	514	1,356
Investments property, plant and equipment and intangible assets*		-138	-184	-243	-327	-793
Investment in associate companies and bio-based start-ups*	4	-56	-55	-112	-55	-132
Other capital transactions		7	5	11	9	18
Cash flow from investing activities		-187	-234	-344	-373	-907
Dividends		-475	-424	-475	-424	-424
Proceeds from exercise of options/shares to employees	10	-	2	50	32	48
Buy-back of treasury shares	7	-44	-2	-68	-12	-30
Gain/(loss) on hedges for net investments in subsidiaries		-22	28	27	100	100
Proceeds from interest-bearing liabilities	11	400	650	512	750	950
Repayment from interest-bearing liabilities	11	-293	-479	-423	-550	-1,047
Change in interest-bearing liabilities/other instruments	11	14	-19	-3	-56	-56
Cash flow from financing activities		-420	-244	-380	-160	-459
Change in cash and cash equivalents		88	-93	48	-19	-10

THE GROUP'S INTERIM CONDENSED CASH FLOW STATEMENT CONT.

Amounts in NOK million	Note	1.4-30.6		1.1-30.6		1.1-31.12
		2026	2025	2026	2025	2,025
Cash and cash equivalents at beginning of period		-64	65	-16	-3	-3
Change in cash and cash equivalents		88	-93	48	-19	-10
Currency effects cash and cash equivalents		9	1	1	-5	-3
Cash and cash equivalents at the close of the period	11	33	-27	33	-27	-16
*Investment by category						
Replacement investments		88	95	149	212	576
Expansion investments ¹⁾ including investments in associate companies and bio-based-start-ups		106	144	206	170	349
Total investments including investment in associate companies and bio-based start-ups		194	239	355	382	925

¹ [Alternative Performance Measures](#), see page 25 for definition.

NOTES

NOTE 01 Organisation and basis for preparation

GENERAL INFORMATION

Borregaard ASA is incorporated and domiciled in Norway. The address of its registered office is Hjalmar Wessels vei 6, Sarpsborg.

The same accounting principles and methods of calculation have been applied as in the Consolidated Financial Statements for 2025 for the Borregaard Group.

Basis for preparation

These unaudited Interim Condensed Consolidated Financial Statements are prepared in accordance with IAS 34 Interim Financial Reporting. Borregaard ASA is the parent company of the Borregaard Group presented in these Interim Condensed Consolidated Financial Statements.

Use of estimates

The same use of estimates has been applied as in the Consolidated Financial Statements for 2025.

NOTE 02 Segments

OPERATING REVENUES

	1.4-30.6		1.1-30.6		1.1-31.12
Amounts in NOK million	2026	2025	2,026	2,025	2025
Borregaard	2,114	2,045	4,119	4,081	7,713
BioSolutions	1,153	1,149	2,220	2,328	4,396
BioMaterials	773	741	1,502	1,430	2,691
Fine Chemicals	198	168	418	347	670
Eliminations	-10	-13	-21	-24	-44

There is limited intercompany sales between the different segments and eliminations consist essentially of allocations from the corporate headquarter.

¹ [Alternative Performance Measures](#), see page 25 for definition.

EBITDA¹

	1.4-30.6		1.1-30.6		1.1-31.12
Amounts in NOK million	2026	2025	2026	2025	2025
Borregaaard	515	522	943	1,033	1,878
BioSolutions	306	338	566	687	1,209
BioMaterials	151	143	253	256	495
Fine Chemicals	58	41	124	90	174

Reconciliation against operating profit & profit before tax

EBITDA ¹	515	522	943	1,033	1,878
Depreciations and write downs	-148	-142	-300	-285	-587
Amortisation intangible assets	-	-2	-	-3	-4
Other income and expenses ¹	-30	-	-30	-	-
Operating profit	337	378	613	745	1,287
Financial items, net	-382	-52	-428	-100	-423
Profit before taxes	-45	326	185	645	864

SALES REVENUES

	1.4-30.6		1.1-30.6		1.1-31.12
Amounts in NOK million	2026	2025	2026	2025	2025
Borregaard	2,076	2,020	4,054	4,012	7,580
BioSolutions	1,126	1,120	2,169	2,258	4,275
BioMaterials	754	734	1,472	1,411	2,643
Fine Chemicals	196	166	413	343	662
Eliminations	-	-	-	-	-

Operating revenues consist of sales revenues and other revenues such as commissions, revenues from waste received for incineration etc.

NOTE 03 Other income and expenses

In connection with the planned construction of a new bridge across the Glomma River by Østfold County, the County Authority has identified a requirement for stabilisation measures at Borregaard's site to mitigate the risk of landslides. The County Authority has suggested to designate the area and impose restrictions in its draft zoning plan for the new bridge. Based on the progress of the planning process and the feedback received from the relevant authorities, Borregaard considers it highly probable that the plan will be adopted substantially in accordance with the current proposal. Borregaard considers it essential that the area is excluded from the zoning plan prior to its adoption. As of 30 June 2026, Borregaard has accrued NOK 30 million and recognised the cost as Other income and expenses¹. The provision is based on Borregaard's best estimate of the costs required to undertake the safeguarding measures. The related works are expected to commence in the 3rd quarter of 2026.

The measures are intended to prevent any loss of value to the area and to ensure that no additional measures are required as part of the project that could adversely affect Borregaard's day-to-day operations.

The provision is based on management's best estimate of the costs required to undertake the safeguarding measures. The required ground stabilisation measures are associated with the County Authority's construction project for the new bridge.

NOTE 04 Financial items

NET FINANCIAL ITEMS

Amounts in NOK million	1.4-30.6		1.1-30.6		1.1-31.12
	2026	2025	2026	2025	2025
Net interest expenses	-30	-37	-59	-73	-134
Currency gain/loss	3	-2	2	-9	-11
Share of profit/-loss from associates	-348	-9	-364	-26	-279
Other financial items, net	-7	-4	-7	8	1
Net financial items	-382	-52	-428	-100	-423

As of 30 June 2026, Borregaard holds 42% of the shares in Alginor ASA. In addition, Borregaard participated in the second tranche of a convertible loan to Alginor of NOK 56 million in the 1st quarter of 2026 and in a new convertible loan of NOK 56 million in the 2nd quarter. See Note 14.

Borregaard also holds 12% of the shares in Kaffe Bueno ApS.

Share of profit/-loss from associates include impairment of investment in Alginor of NOK 337 million. See Note 14.

Other financial items, net includes changes in committed return on the Group's unfunded pension plan.

¹ [Alternative Performance Measures](#), see page 25 for definition.

NOTE 5 Income tax expense

The tax rate of -72.4% (23.3%) for the first six months of 2026 is a compilation of the tax rates in the various countries in which Borregaard operates and has taxable income. The corporate income tax rate in Norway is 22%. Excluding ground stabilisation measures and impairment of Alginor, the tax rate was 24.3% in the first six months of 2026.

In addition to the compilation of the tax rates in the various countries in which Borregaard operates and has taxable income, the income tax rate for the Group is also impacted by the following: LignoTech Florida is a limited liability company (LLC) which is taxed on the owners hand. Profit before tax is 100% consolidated in the Borregaard Group, whereas the tax expense is calculated based on Borregaard's 55% ownership. Consequently, profit attributable to non-controlling interests for LignoTech Florida (45%) is calculated on profit before tax.

Share of profit after tax from the associated companies, Alginor ASA and Kaffe Bueno ApS, is accounted for as part of operating profit and profit before tax. There are carry forward losses on the Group which will not be recognised as deferred tax asset, and hence increase the Group's tax rate.

NOTE 06 Earnings per share (EPS)

The share capital consists of 100 million shares. The company holds 355,404 treasury shares and average number of outstanding shares as of 30 June 2026 were 99.84 million. Average number of outstanding diluted shares were 99.77 million (99.69 in 2025).

Earnings per diluted share were NOK -1.27 in the 2nd quarter of 2026 (NOK 2.56 in the 2nd quarter of 2025). Excluding ground stabilisation measures and impairment of Alginor, earnings per share were NOK 2.35 in the quarter and NOK 4.17 for the first six months of 2026.

¹ [Alternative Performance Measures](#), see page 25 for definition.

NOTE 07 Stock options

No share options were exercised during the 2nd quarter 2026.

The Group Executive Management and other key employees hold a total of 1,234,500 stock options in six different share option programmes in Borregaard.

Stock options	Issued 2022	Issued 2023	Issued 2024	Issued Feb 2025	Issued Aug 2025	Issued 2026
Number of stock options	200,000	244,000	371,000	389,500	30,000	393,000
Strike price*	207.75	178.00	186.35	212.22	214.56	188.52
Vesting period	3 years	3 years	3 years	3 years	3 years	3 years
Expiry date	17.02.2027	01.03.2028	27.02.2029	14.02.2030	01.08.2030	23.02.2031

*Strike prices have been adjusted for dividend paid since issuance of stock options.

NOTE 08 Statement of comprehensive income

The statement of comprehensive income presents the changes in the value of hedging instruments, including both cash flow hedges and hedges of net investments in subsidiaries, which are reflected in the hedging reserve.

These amounts are shown net of tax.

Amounts in NOK million	30.6.2026		30.6.2025		31.12.2025	
	Cash flow hedges	Hedges of net investments in subsidiaries	Cash flow hedges	Hedges of net investments in subsidiaries	Cash flow hedges	Hedges of net investments in subsidiaries
Tax effect year-to-date	51	-69	-8	-75	8	-74
Hedging reserve after tax	190	-216	-31	-232	28	-230

NOTE 09 Fair value hierarchy

For financial instruments that are recognised at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation at the end of each reporting period.

The following measurement levels are used for determining the fair value of financial instruments:

- Level 1** - Quoted market prices in an active market (that are unadjusted) for identical assets or liabilities
- Level 2** - Valuation techniques (for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable)
- Level 3** - Valuation techniques (for which the lowest level input that is significant to the fair value measurement is unobservable)

There were no transfers from one level to another in the measurement hierarchy from the 1st quarter of 2026 to the 2nd quarter of 2026.

Borregaard consequently has no items defined as level 1. The green bond is determined as measurement level 3. The fair value of the bond is deemed to equal its book value.

Set out below is a comparison of the carrying amount and the fair value of financial instruments as of 30 June 2026:

Amounts in NOK million	Level	30.6.2026		31.12.2025	
		Carrying amount	Fair value	Carrying amount	Fair value
FINANCIAL ASSETS					
Non-current financial receivables	2	172	172	176	176
Non-current derivatives	2	162	162	89	89
Share investments	2	17	17	17	17
Current derivatives	2	145	145	74	74
Total financial assets		496	496	356	356

FINANCIAL LIABILITIES

Non-current financial liabilities	2, 3	1,648	1,648	1,720	1,720
Non-current derivatives	2	39	39	68	68
Current financial liabilities	2	620	620	463	463
Current derivatives	2	39	39	50	50
Total financial liabilities		2,346	2,346	2,301	2,301

FINANCIAL INSTRUMENT MEASURED AT FAIR VALUE

Amounts in NOK million	Level 1		Level 2	Level 3
Financial instruments 30.6.2026	-1,850	-	-1,350	-500
Financial instruments 31.12.2025	-1,945	-	-1,445	-500

The financial instruments are measured based on observable spot exchange rates, the yield curves of the respective currencies as well as the currency basis spreads between the respective currencies.

NOTE 10 Compilation of Equity

Amounts in NOK million	30.6.2026	31.12.2025
Share capital	100	100
Treasury shares	-	-
Share premium	1,346	1,346
Other paid-in capital	1,165	1,097
Translation effects	245	265
Hedging reserve (after tax)	-26	-202
Actuarial gains/Losses	147	147
Retained earnings	2,612	3,100
Group equity (controlling interests)	5,589	5,853

As of 30 June 2026, the company held 355,404 treasury shares at an average cost of NOK 150.41.

NOTE 12 Related parties

The members of the Group Executive Management of Borregaard held a total of 427,000 stock options in the Company as of 30 June 2026.

NOTE 13 Assessments relating to impairment

See Note 14 for impairment related to Alginor as of 30 June 2026. No other impairment indicators have been identified in the Borregaard Group’s property, plant and equipment or intangible assets in the 2nd quarter of 2026.

NOTE 11 Net interest-bearing debt¹

The various elements of net interest-bearing debt are shown in the following table:

Amounts in NOK million	30.6.2026	31.12.2025
Non-current interest-bearing liabilities	1,646	1,718
Current interest-bearing liabilities including overdraft of cashpool	620	463
Non-current interest-bearing receivables (included in "Other Assets")	-	-
Cash and cash deposits	-125	-91
Net interest-bearing liabilities	2,141	2,090
-Of which IFRS 16 Leases	450	497

¹ [Alternative Performance Measures](#), see page 25 for definition.

NOTE 14 Other matters and subsequent events

Proposed restructuring and impairment of Alginor

In recent months, Alginor has faced challenges relating to raw material supply, delays in product development and commercialisation, and further cost overruns associated with the investment in its demonstration plant. See notification to the Oslo Stock Exchange on 28 May 2026.

Borregaard considers it unlikely that the current value of Alginor exceeds the company's bank debt and other prioritised obligations. Accordingly, Borregaard's view is that its shareholding in Alginor and convertible loans to the company have no recoverable value.

Against this background and based on proposed share transactions at no consideration between Borregaard and Hatteland, Borregaard has recognised an impairment loss of NOK 337 million in the 2nd quarter relating to its equity investment in Alginor and the convertible loans granted to the company.

Following the impairment, the carrying value of Borregaard's investment in Alginor is nil as of 30 June 2026.

The three main shareholders in Alginor - Borregaard, Must Invest and Hatteland, with Hatteland as acting lead investor - have offered Alginor to guarantee for NOK 100 million in new equity. The offer is subject to corporate approvals in Alginor.

Borregaard has committed to subscribe for up to NOK 10 million of the proposed NOK 100 million equity injection. Upon completion of the proposed restructuring, Borregaard's ownership interest in Alginor will be 10%. For more information, see <https://alginor.no/investors/reports-information/>.

There have been no events after the balance sheet date that would have had a material impact on the interim financial statements, or the assessments carried out.

ALTERNATIVE PERFORMANCE MEASURES

In the discussion of the reported operating results, financial position and cash flows, Borregaard refers to certain measures which are not defined by generally accepted accounting principles (GAAP) such as IFRS. Borregaard management makes regular use of these Alternative Performance Measures and is of the opinion that this information, along with

comparable GAAP measures, is useful to investors who wish to evaluate the company's operating performance, ability to repay debt and capability to pursue new business opportunities. Such Alternative Performance Measures should not be viewed in isolation or as an alternative to the equivalent GAAP measure.



EBITDA

Description
EBITDA is defined by Borregaard as operating profit before depreciation, amortisation and other income and expenses.

Reason for including
Shows performance regardless of capital structure, tax situation and adjusted for income and expenses related transactions and events not considered by management to be part of operating activities. Management believes the measure enables an evaluation of operating performance.

	1.4-30.6		1.1-30.6		1.1-31.12
	2026	2025	2026	2025	2025
EBITDA					
Operating profit	337	378	613	745	1,287
Other income and expenses	30	-	30	-	-
Amortisation intangible assets	-	2	-	3	4
Depreciation and impairment property, plant and	148	142	300	285	587
EBITDA	515	522	943	1,033	1,878

EBITDA MARGIN

Description
EBITDA margin is defined by Borregaard as EBITDA divided by operating revenues.

Reason for including
Shows the operations’ performance regardless of capital structure and tax situation as a ratio to operating revenue.

	1.4-30.6		1.1-30.6		1.1-31.12
	2026	2025	2026	2025	2025
EBITDA MARGIN					
EBITDA	515	522	943	1,033	1,878
Operating revenues	2,114	2,045	4,119	4,081	7,713
EBITDA margin (%) (EBITDA/operating revenues)	24.4	25.5	22.9	25.3	24.3

EQUITY RATIO

Description
Equity ratio is defined by Borregaard as equity (including non-controlling interests) divided by equity and liabilities.

Reason for including
Equity ratio is an important measure in describing the capital structure.

EQUITY RATIO	30.06.2026	30.06.2025	31.12.2025
Total equity	5,610	5,678	5,878
Equity & liabilities	9,506	9,963	9,670
Equity ratio (%) (total equity/equity & liabilities)	59.0	57.0	60.8

EXPANSION INVESTMENTS

Description

Borregaard’s investments are either categorised as replacement or expansion. Expansion investments is defined by Borregaard as investments made in order to expand production capacity, produce new products or to improve the performance of existing products. Such investments include business acquisitions, investments in bio-based start-ups, pilot plants, capitalised research and development costs and new distribution set-ups.

Reason for including

Borregaard’s strategic priorities are specialisation and diversification, increase value added from the biorefinery, develop business areas and to continue emphasis on ESG along the entire value chain. To be able to deliver on those priorities, expansion investments are needed. As such, expansion investments are important information for investors. One of Borregaard’s financial objectives is to have an internal rate of return >15% pre-tax for expansion investments.

EXPANSION INVESTMENTS	1.4-30.6		1.1-30.6		1.1-31.12
	2026	2025	2026	2025	2025
Total investments including investments in associate companies and bio-based start-ups	194	239	355	382	925
Replacement investments	-88	-95	-149	-212	-576
Expansion investments including investments in associate companies and bio-based start-ups	106	144	206	170	349

OTHER INCOME AND EXPENSES

Description

Other income and expenses are defined by Borregaard as non-recurring items or items related to other periods or to a discontinued business or activity. These items are not viewed as reliable indicators of future earnings based on the business areas’ normal operations. These items will be included in the Group's operating profit.

Reason for including

To be able to compare the EBITDA of different reporting periods, significant non-recurring items not directly related to operating activities, are included in Other income and expenses.

OTHER INCOME AND EXPENSES	1.4-30.6		1.1-30.6		1.1-31.12
	2026	2025	2026	2025	2025
Other income and expenses	-30	-	-30	-	-

NET INTEREST-BEARING DEBT

Description	Reason for including	NET INTEREST-BEARING DEBT			
Net interest-bearing debt is defined by Borregaard as interest-bearing liabilities minus interest-bearing assets.	Net interest-bearing debt provides an indicator of the net indebtedness and an indicator of the overall strength of the statement of financial position. Net interest-bearing debt is part of Borregaard’s financial covenants (leverage ratio) and is important in understanding the capital structure.	30.06.2026	30.06.2025	31.12.2025	
		Non-current interest-bearing liabilities	1,646	1,765	1,718
		Current interest-bearing liabilities including overdraft of cashpool	620	687	463
		Non-current interest-bearing receivables (included in "Other assets")	-	-1	-
		Cash and cash deposits	-125	-96	-91
		Net interest-bearing debt	2,141	2,355	2,090

LEVERAGE RATIO

Description	Reason for including	LEVERAGE RATIO			
Leverage ratio is defined by Borregaard as net interest bearing debt divided by last twelve months' (LTM) EBITDA.	Leverage ratio is an indicator of the overall strength of the statement of financial position. Borregaard has a targeted leverage ratio between 1.0 and 2.25 over time. Leverage ratio is Borregaard's financial covenant on long-term credit facilities.	30.06.2026	30.06.2025	31.12.2025	
		Net interest-bearing debt	2,141	2,355	2,090
		EBITDA	1,788	1,955	1,878
		Leverage ratio (net interest-bearing debt/EBITDA)	1.20	1.20	1.11

CAPITAL EMPLOYED

Description	Reason for including	CAPITAL EMPLOYED (END OF PERIOD)	30.06.2026	30.06.2025	31.12.2025
Capital employed is defined by Borregaard as the total of net working capital, intangible assets, property, plant and equipment, right-of-use assets minus net pension liabilities.	Borregaard uses capital employed as basis for calculating ROCE.	Capital employed (end of period)	8,060	8,292	8,237

RETURN ON CAPITAL EMPLOYED (ROCE)

Description	Reason for including
Return on capital employed (ROCE) is defined by Borregaard as last twelve months' (LTM) capital contribution (operating profit before amortisation and other income and expenses) divided by average capital employed based on the ending balance of the last five quarters.	ROCE is an important financial ratio to assess Borregaard's profitability and capital efficiency. One of Borregaard's financial objectives is to have ROCE >15% pre-tax over a business cycle.

RETURN ON CAPITAL EMPLOYED (ROCE)	30.06.2026	30.06.2025	31.12.2025
Capital employed end of:			
Q2, 2024	-	7,582	-
Q3, 2024	-	7,813	-
Q4, 2024	-	8,172	8,172
Q1, 2025	-	8,290	8,290
Q2, 2025	8,292	8,292	8,292
Q3, 2025	8,247	-	8,247
Q4, 2025	8,237	-	8,237
Q1, 2026	8,445	-	-
Q2, 2026	8,060	-	-
Average capital employed	8,256	8,030	8,248
Capital contribution	30.06.2026	30.06.2025	31.12.2025
Operating profit	1,155	1,346	1,287
Other income and expenses	30	30	-
Amortisation intangible assets	1	5	4
Capital contribution	1,186	1,381	1,291
RETURN ON CAPITAL EMPLOYED (ROCE)	30.06.2026	30.06.2025	31.12.2025
Capital contribution	1,186	1,381	1,291
Average capital employed	8,256	8,030	8,248
Return on capital employed (ROCE) (%) (capital contribution/ average capital employed)	14.4	17.2	15.7



Q2 2026



Borregaard ASA
P.O. Box 162, NO-1701 Sarpsborg, Norway
Telephone: (+47) 69 11 80 00
E-mail: Borregaard@borregaard.com

Fax: (+47) 69 11 87 70
www.borregaard.com